Abstract: Hormone receptor-positive breast cancer shows significant long-term risk of recurrence, even after receiving adjuvant endocrine therapy for five years. It is a problem to be solved whether to extend adjuvant endocrine therapy. Recent clinical trials offered more evidences for this question. We will overview the path to extending adjuvant endocrine therapy in hormone-receptor positive early breast cancer.